Health TidingsOno Leverages Congruence Revenir™ for Neurology, Immunology Breakthroughs Ono Leverages Congruence Revenir™ for Neurology, Immunology Breakthroughs Read Post »
Health TidingsAtara and Pierre Fabre Seek FDA Type A Meeting to Advance Tab-Cel After CRL Atara and Pierre Fabre Seek FDA Type A Meeting to Advance Tab-Cel After CRL Read Post »
Health TidingsFDA Grants Rare Public Hearing on Vanda’s HETLIOZ® Jet Lag Approval ... FDA Grants Rare Public Hearing on Vanda’s HETLIOZ® Jet Lag Approval ... Read Post »
Policy & AcquisitionsCullgen Joins Gyre in $300M Pact, Boosting Protein Degraders Cullgen Joins Gyre in $300M Pact, Boosting Protein Degraders Read Post »
Clinical TrailsMerck, Eisai Advance Dual Oral Therapy with Strong Phase 3 RCC Data at ASCO... Merck, Eisai Advance Dual Oral Therapy with Strong Phase 3 RCC Data at ASCO... Read Post »
Health TidingsPhase 3 Setback for Aardvark’s ARD-101 as HERO Enrollment Freezes Phase 3 Setback for Aardvark’s ARD-101 as HERO Enrollment Freezes Read Post »
Clinical Trails55% Risk Reduction: Ralinepag’s ADVANCE OUTCOMES Results Signal New P... 55% Risk Reduction: Ralinepag’s ADVANCE OUTCOMES Results Signal New P... Read Post »
New Drug ApprovalHERNEXEOS® Gains FDA Nod as First-Line Option for HER2-Mutant NSCLC HERNEXEOS® Gains FDA Nod as First-Line Option for HER2-Mutant NSCLC Read Post »
Health TidingsIntellia Gains Complete FDA Greenlight for Nex-z ATTR Trials Post-Hold Reso... Intellia Gains Complete FDA Greenlight for Nex-z ATTR Trials Post-Hold Reso... Read Post »
Health TidingsJohnson & Johnson Unveils Promising Phase 1b Data for Pasritamig Plus D... Johnson & Johnson Unveils Promising Phase 1b Data for Pasritamig Plus D... Read Post »
New Drug ApprovalFDA Approves Once-Weekly YUVIWEL® for Pediatric Achondroplasia FDA Approves Once-Weekly YUVIWEL® for Pediatric Achondroplasia Read Post »
Clinical TrailsAbbVie’s SKYRIZI Shows Strong Induction Results in Hard-to-Treat Crohn’... AbbVie’s SKYRIZI Shows Strong Induction Results in Hard-to-Treat Crohn’... Read Post »
Health TidingsHuntington’s Hope Dims? FDA Urges Sham-Controlled Trial for uniQure AMT-1... Huntington’s Hope Dims? FDA Urges Sham-Controlled Trial for uniQure AMT-1... Read Post »
Health TidingsRoche Fenebrutinib Phase III Success: 51% Fewer MS Relapses Roche Fenebrutinib Phase III Success: 51% Fewer MS Relapses Read Post »
Clinical TrailsMerck Reports Positive Phase 3 Results Across Ovarian, Bladder, and Renal C... Merck Reports Positive Phase 3 Results Across Ovarian, Bladder, and Renal C... Read Post »
Health TidingsFDA Accepts BLA for Imsidolimab: A Precision Therapy Poised to Transform Ge... FDA Accepts BLA for Imsidolimab: A Precision Therapy Poised to Transform Ge... Read Post »
Clinical TrailsSystImmune and BMS Report Dual PFS/OS Wins for Iza-Bren in Advanced TNBC Ph... SystImmune and BMS Report Dual PFS/OS Wins for Iza-Bren in Advanced TNBC Ph... Read Post »
Clinical TrailsOrganon Highlights VTAMA Family Sleep Benefits in ADORING Trials Organon Highlights VTAMA Family Sleep Benefits in ADORING Trials Read Post »
Health TidingsOno Pharmaceutical Ends Forxiga Partnership with AstraZeneca in Japan Ono Pharmaceutical Ends Forxiga Partnership with AstraZeneca in Japan Read Post »
Lifestyle WellnessMelatonin for Better Sleep: Mechanisms and Evidence from Clinical Trials Melatonin for Better Sleep: Mechanisms and Evidence from Clinical Trials Read Post »
